Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer
The present study characterized the psychiatric diagnoses and symptoms that led to the administration of antipsychotic medications in children and adolescents with cancer, and to evaluate the benefits and tolerability of these drugs in a large hospital-based pediatric hematology-oncology practice. E...
Gespeichert in:
| Veröffentlicht in: | Journal of child and adolescent psychopharmacology 2020-10, Vol.30 (8), p.486-494 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 494 |
|---|---|
| container_issue | 8 |
| container_start_page | 486 |
| container_title | Journal of child and adolescent psychopharmacology |
| container_volume | 30 |
| creator | Peled, Orit Lavan, Orly Stein, Jerry Vinograd, Inbal Yahel, Anat Valevski, Avi Weizman, Abraham Kimmel-Tamir, Ella Apter, Alan Fennig, Silvana Yaniv, Isaac Bernfeld, Yael Benaroya-Milshtein, Noa |
| description | The present study characterized the psychiatric diagnoses and symptoms that led to the administration of antipsychotic medications in children and adolescents with cancer, and to evaluate the benefits and tolerability of these drugs in a large hospital-based pediatric hematology-oncology practice.
Efficacy and adverse effects of two second-generation antipsychotics were retrospectively analyzed in 43 patients 2.9-19.6 (mean 12.1) years of age. The Clinical Global Impression-Severity (CGI-S) Scale and Improvement (CGI-I) Scale were used to evaluate psychiatric symptom severity before and following treatment, while the incidence of side effects and drug-drug interactions were collected from medical records.
Olanzapine was administered to 58% of patients and risperidone to 42%; the choice of drug was at the discretion of the treating psychiatrist. The common psychiatric diagnoses among these patients included adjustment disorder (37%) and medication-induced psychiatric disorders (23%). The most common psychiatric-medical symptoms included irritability/agitation (79%) and depressed mood (74%). CGI-S improved significantly (
|
| doi_str_mv | 10.1089/cap.2019.0164 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2449460613</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2449460613</sourcerecordid><originalsourceid>FETCH-LOGICAL-c321t-a485d5e426cd4eff8e83d7cf2eeb1d0bc4bf28196a64efcce80c668068f69c103</originalsourceid><addsrcrecordid>eNo9kV9PwjAUxRujEUQffTVNfB62XVc635D4L4FAIjwvpetcydbOtoTwNfzEFkGf7k3uub-TnAPALUZDjHj-IEU3JAjnQ4QZPQN9nGWjhOc5OY87ojTJKEt74Mr7DUI4ZYhdgl5KOM1GJO-D74Xfy9p2tXCtkLaxn3uoDQy1ggtVahGclnBuThdhSvhkjYIz4ZzdwaUTxneNMAGujA7-EY5N0N0vMsTHWURIEbQ1Hi5E00Segh_7tgu29QefSa2b0ikDdzrUcCKMVO4aXFSi8ermNAdg9fK8nLwl0_nr-2Q8TWRKcEgE5VmZKUqYLKmqKq54Wo5kRZRa4xKtJV1XhOOcCRbPUiqOJGMcMV6xXGKUDsD9kds5-7VVPhQbu3UmWhaE0pzGqHAaVclRJZ313qmq6JxuhdsXGBWHBorYQHFooDg0EPV3J-p23aryX_0XefoDrCWFHw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2449460613</pqid></control><display><type>article</type><title>Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer</title><source>Alma/SFX Local Collection</source><creator>Peled, Orit ; Lavan, Orly ; Stein, Jerry ; Vinograd, Inbal ; Yahel, Anat ; Valevski, Avi ; Weizman, Abraham ; Kimmel-Tamir, Ella ; Apter, Alan ; Fennig, Silvana ; Yaniv, Isaac ; Bernfeld, Yael ; Benaroya-Milshtein, Noa</creator><creatorcontrib>Peled, Orit ; Lavan, Orly ; Stein, Jerry ; Vinograd, Inbal ; Yahel, Anat ; Valevski, Avi ; Weizman, Abraham ; Kimmel-Tamir, Ella ; Apter, Alan ; Fennig, Silvana ; Yaniv, Isaac ; Bernfeld, Yael ; Benaroya-Milshtein, Noa</creatorcontrib><description>The present study characterized the psychiatric diagnoses and symptoms that led to the administration of antipsychotic medications in children and adolescents with cancer, and to evaluate the benefits and tolerability of these drugs in a large hospital-based pediatric hematology-oncology practice.
Efficacy and adverse effects of two second-generation antipsychotics were retrospectively analyzed in 43 patients 2.9-19.6 (mean 12.1) years of age. The Clinical Global Impression-Severity (CGI-S) Scale and Improvement (CGI-I) Scale were used to evaluate psychiatric symptom severity before and following treatment, while the incidence of side effects and drug-drug interactions were collected from medical records.
Olanzapine was administered to 58% of patients and risperidone to 42%; the choice of drug was at the discretion of the treating psychiatrist. The common psychiatric diagnoses among these patients included adjustment disorder (37%) and medication-induced psychiatric disorders (23%). The most common psychiatric-medical symptoms included irritability/agitation (79%) and depressed mood (74%). CGI-S improved significantly (
< 0.001) between assessments, with no statistically significant difference between olanzapine- and risperidone-treated patients. CGI-I scores at reassessment indicated superiority of olanzapine as compared with risperidone. Adverse effects of treatment were mild.
Olanzapine and risperidone can be well tolerated and ameliorate severe psychiatric-medical symptoms in children and adolescents with cancer. The potential palliative benefits of these second-generation antipsychotics (e.g., rapid onset of action, antiemesis, sedation, and appetite stimulation) increase the utility of their use in children treated in oncology and bone marrow transplant units.</description><identifier>ISSN: 1044-5463</identifier><identifier>EISSN: 1557-8992</identifier><identifier>DOI: 10.1089/cap.2019.0164</identifier><identifier>PMID: 32845729</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adolescents ; Antipsychotics ; Anxiety ; Appetite ; Bone marrow transplantation ; Cancer ; Cancer therapies ; Children ; Children & youth ; Drug interactions ; Hematology ; Medical records ; Mental disorders ; Mood ; Olanzapine ; Oncology ; Patients ; Pediatrics ; Psychopharmacology ; Psychotropic drugs ; Quality of life ; Risperidone ; Side effects ; Statistical analysis ; Stem cell transplantation ; Transplants & implants ; Variance analysis</subject><ispartof>Journal of child and adolescent psychopharmacology, 2020-10, Vol.30 (8), p.486-494</ispartof><rights>Copyright Mary Ann Liebert, Inc. Oct 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c321t-a485d5e426cd4eff8e83d7cf2eeb1d0bc4bf28196a64efcce80c668068f69c103</citedby><cites>FETCH-LOGICAL-c321t-a485d5e426cd4eff8e83d7cf2eeb1d0bc4bf28196a64efcce80c668068f69c103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32845729$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peled, Orit</creatorcontrib><creatorcontrib>Lavan, Orly</creatorcontrib><creatorcontrib>Stein, Jerry</creatorcontrib><creatorcontrib>Vinograd, Inbal</creatorcontrib><creatorcontrib>Yahel, Anat</creatorcontrib><creatorcontrib>Valevski, Avi</creatorcontrib><creatorcontrib>Weizman, Abraham</creatorcontrib><creatorcontrib>Kimmel-Tamir, Ella</creatorcontrib><creatorcontrib>Apter, Alan</creatorcontrib><creatorcontrib>Fennig, Silvana</creatorcontrib><creatorcontrib>Yaniv, Isaac</creatorcontrib><creatorcontrib>Bernfeld, Yael</creatorcontrib><creatorcontrib>Benaroya-Milshtein, Noa</creatorcontrib><title>Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer</title><title>Journal of child and adolescent psychopharmacology</title><addtitle>J Child Adolesc Psychopharmacol</addtitle><description>The present study characterized the psychiatric diagnoses and symptoms that led to the administration of antipsychotic medications in children and adolescents with cancer, and to evaluate the benefits and tolerability of these drugs in a large hospital-based pediatric hematology-oncology practice.
Efficacy and adverse effects of two second-generation antipsychotics were retrospectively analyzed in 43 patients 2.9-19.6 (mean 12.1) years of age. The Clinical Global Impression-Severity (CGI-S) Scale and Improvement (CGI-I) Scale were used to evaluate psychiatric symptom severity before and following treatment, while the incidence of side effects and drug-drug interactions were collected from medical records.
Olanzapine was administered to 58% of patients and risperidone to 42%; the choice of drug was at the discretion of the treating psychiatrist. The common psychiatric diagnoses among these patients included adjustment disorder (37%) and medication-induced psychiatric disorders (23%). The most common psychiatric-medical symptoms included irritability/agitation (79%) and depressed mood (74%). CGI-S improved significantly (
< 0.001) between assessments, with no statistically significant difference between olanzapine- and risperidone-treated patients. CGI-I scores at reassessment indicated superiority of olanzapine as compared with risperidone. Adverse effects of treatment were mild.
Olanzapine and risperidone can be well tolerated and ameliorate severe psychiatric-medical symptoms in children and adolescents with cancer. The potential palliative benefits of these second-generation antipsychotics (e.g., rapid onset of action, antiemesis, sedation, and appetite stimulation) increase the utility of their use in children treated in oncology and bone marrow transplant units.</description><subject>Adolescents</subject><subject>Antipsychotics</subject><subject>Anxiety</subject><subject>Appetite</subject><subject>Bone marrow transplantation</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Children</subject><subject>Children & youth</subject><subject>Drug interactions</subject><subject>Hematology</subject><subject>Medical records</subject><subject>Mental disorders</subject><subject>Mood</subject><subject>Olanzapine</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Psychopharmacology</subject><subject>Psychotropic drugs</subject><subject>Quality of life</subject><subject>Risperidone</subject><subject>Side effects</subject><subject>Statistical analysis</subject><subject>Stem cell transplantation</subject><subject>Transplants & implants</subject><subject>Variance analysis</subject><issn>1044-5463</issn><issn>1557-8992</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNo9kV9PwjAUxRujEUQffTVNfB62XVc635D4L4FAIjwvpetcydbOtoTwNfzEFkGf7k3uub-TnAPALUZDjHj-IEU3JAjnQ4QZPQN9nGWjhOc5OY87ojTJKEt74Mr7DUI4ZYhdgl5KOM1GJO-D74Xfy9p2tXCtkLaxn3uoDQy1ggtVahGclnBuThdhSvhkjYIz4ZzdwaUTxneNMAGujA7-EY5N0N0vMsTHWURIEbQ1Hi5E00Segh_7tgu29QefSa2b0ikDdzrUcCKMVO4aXFSi8ermNAdg9fK8nLwl0_nr-2Q8TWRKcEgE5VmZKUqYLKmqKq54Wo5kRZRa4xKtJV1XhOOcCRbPUiqOJGMcMV6xXGKUDsD9kds5-7VVPhQbu3UmWhaE0pzGqHAaVclRJZ313qmq6JxuhdsXGBWHBorYQHFooDg0EPV3J-p23aryX_0XefoDrCWFHw</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Peled, Orit</creator><creator>Lavan, Orly</creator><creator>Stein, Jerry</creator><creator>Vinograd, Inbal</creator><creator>Yahel, Anat</creator><creator>Valevski, Avi</creator><creator>Weizman, Abraham</creator><creator>Kimmel-Tamir, Ella</creator><creator>Apter, Alan</creator><creator>Fennig, Silvana</creator><creator>Yaniv, Isaac</creator><creator>Bernfeld, Yael</creator><creator>Benaroya-Milshtein, Noa</creator><general>Mary Ann Liebert, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7RV</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>202010</creationdate><title>Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer</title><author>Peled, Orit ; Lavan, Orly ; Stein, Jerry ; Vinograd, Inbal ; Yahel, Anat ; Valevski, Avi ; Weizman, Abraham ; Kimmel-Tamir, Ella ; Apter, Alan ; Fennig, Silvana ; Yaniv, Isaac ; Bernfeld, Yael ; Benaroya-Milshtein, Noa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c321t-a485d5e426cd4eff8e83d7cf2eeb1d0bc4bf28196a64efcce80c668068f69c103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescents</topic><topic>Antipsychotics</topic><topic>Anxiety</topic><topic>Appetite</topic><topic>Bone marrow transplantation</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Children</topic><topic>Children & youth</topic><topic>Drug interactions</topic><topic>Hematology</topic><topic>Medical records</topic><topic>Mental disorders</topic><topic>Mood</topic><topic>Olanzapine</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Psychopharmacology</topic><topic>Psychotropic drugs</topic><topic>Quality of life</topic><topic>Risperidone</topic><topic>Side effects</topic><topic>Statistical analysis</topic><topic>Stem cell transplantation</topic><topic>Transplants & implants</topic><topic>Variance analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peled, Orit</creatorcontrib><creatorcontrib>Lavan, Orly</creatorcontrib><creatorcontrib>Stein, Jerry</creatorcontrib><creatorcontrib>Vinograd, Inbal</creatorcontrib><creatorcontrib>Yahel, Anat</creatorcontrib><creatorcontrib>Valevski, Avi</creatorcontrib><creatorcontrib>Weizman, Abraham</creatorcontrib><creatorcontrib>Kimmel-Tamir, Ella</creatorcontrib><creatorcontrib>Apter, Alan</creatorcontrib><creatorcontrib>Fennig, Silvana</creatorcontrib><creatorcontrib>Yaniv, Isaac</creatorcontrib><creatorcontrib>Bernfeld, Yael</creatorcontrib><creatorcontrib>Benaroya-Milshtein, Noa</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Journal of child and adolescent psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peled, Orit</au><au>Lavan, Orly</au><au>Stein, Jerry</au><au>Vinograd, Inbal</au><au>Yahel, Anat</au><au>Valevski, Avi</au><au>Weizman, Abraham</au><au>Kimmel-Tamir, Ella</au><au>Apter, Alan</au><au>Fennig, Silvana</au><au>Yaniv, Isaac</au><au>Bernfeld, Yael</au><au>Benaroya-Milshtein, Noa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer</atitle><jtitle>Journal of child and adolescent psychopharmacology</jtitle><addtitle>J Child Adolesc Psychopharmacol</addtitle><date>2020-10</date><risdate>2020</risdate><volume>30</volume><issue>8</issue><spage>486</spage><epage>494</epage><pages>486-494</pages><issn>1044-5463</issn><eissn>1557-8992</eissn><abstract>The present study characterized the psychiatric diagnoses and symptoms that led to the administration of antipsychotic medications in children and adolescents with cancer, and to evaluate the benefits and tolerability of these drugs in a large hospital-based pediatric hematology-oncology practice.
Efficacy and adverse effects of two second-generation antipsychotics were retrospectively analyzed in 43 patients 2.9-19.6 (mean 12.1) years of age. The Clinical Global Impression-Severity (CGI-S) Scale and Improvement (CGI-I) Scale were used to evaluate psychiatric symptom severity before and following treatment, while the incidence of side effects and drug-drug interactions were collected from medical records.
Olanzapine was administered to 58% of patients and risperidone to 42%; the choice of drug was at the discretion of the treating psychiatrist. The common psychiatric diagnoses among these patients included adjustment disorder (37%) and medication-induced psychiatric disorders (23%). The most common psychiatric-medical symptoms included irritability/agitation (79%) and depressed mood (74%). CGI-S improved significantly (
< 0.001) between assessments, with no statistically significant difference between olanzapine- and risperidone-treated patients. CGI-I scores at reassessment indicated superiority of olanzapine as compared with risperidone. Adverse effects of treatment were mild.
Olanzapine and risperidone can be well tolerated and ameliorate severe psychiatric-medical symptoms in children and adolescents with cancer. The potential palliative benefits of these second-generation antipsychotics (e.g., rapid onset of action, antiemesis, sedation, and appetite stimulation) increase the utility of their use in children treated in oncology and bone marrow transplant units.</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>32845729</pmid><doi>10.1089/cap.2019.0164</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1044-5463 |
| ispartof | Journal of child and adolescent psychopharmacology, 2020-10, Vol.30 (8), p.486-494 |
| issn | 1044-5463 1557-8992 |
| language | eng |
| recordid | cdi_proquest_journals_2449460613 |
| source | Alma/SFX Local Collection |
| subjects | Adolescents Antipsychotics Anxiety Appetite Bone marrow transplantation Cancer Cancer therapies Children Children & youth Drug interactions Hematology Medical records Mental disorders Mood Olanzapine Oncology Patients Pediatrics Psychopharmacology Psychotropic drugs Quality of life Risperidone Side effects Statistical analysis Stem cell transplantation Transplants & implants Variance analysis |
| title | Psychopharmacology in the Pediatric Oncology and Bone Marrow Transplant Units: Antipsychotic Medications Palliate Symptoms in Children with Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T21%3A05%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psychopharmacology%20in%20the%20Pediatric%20Oncology%20and%20Bone%20Marrow%20Transplant%20Units:%20Antipsychotic%20Medications%20Palliate%20Symptoms%20in%20Children%20with%20Cancer&rft.jtitle=Journal%20of%20child%20and%20adolescent%20psychopharmacology&rft.au=Peled,%20Orit&rft.date=2020-10&rft.volume=30&rft.issue=8&rft.spage=486&rft.epage=494&rft.pages=486-494&rft.issn=1044-5463&rft.eissn=1557-8992&rft_id=info:doi/10.1089/cap.2019.0164&rft_dat=%3Cproquest_cross%3E2449460613%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2449460613&rft_id=info:pmid/32845729&rfr_iscdi=true |